[
  {
    "ts": null,
    "headline": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
    "summary": "Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.",
    "url": "https://finnhub.io/api/news?id=f58df00bb20b8c43e492a2a40109df7467ae78a0e89aab182a4cab400cb2a554",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743085320,
      "headline": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
      "id": 133481428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.",
      "url": "https://finnhub.io/api/news?id=f58df00bb20b8c43e492a2a40109df7467ae78a0e89aab182a4cab400cb2a554"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
    "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
    "url": "https://finnhub.io/api/news?id=20216feaf8f84f97ca0430e38d06cbf894929f9ccb4967c83b027fb867f382eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743078660,
      "headline": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
      "id": 133471694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
      "url": "https://finnhub.io/api/news?id=20216feaf8f84f97ca0430e38d06cbf894929f9ccb4967c83b027fb867f382eb"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
    "summary": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
    "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743060600,
      "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
      "id": 133467152,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    }
  },
  {
    "ts": null,
    "headline": "How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology",
    "summary": "After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.",
    "url": "https://finnhub.io/api/news?id=001537c9d63008da192689c14cdcb2294b824b9e6b60e58388eb79d4ee37fa02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743060464,
      "headline": "How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology",
      "id": 133468095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.",
      "url": "https://finnhub.io/api/news?id=001537c9d63008da192689c14cdcb2294b824b9e6b60e58388eb79d4ee37fa02"
    }
  }
]